An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving Chemotherapy
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This observational study will evaluate the efficacy and safety of epoetin beta (NeoRecormon)
in participants with symptomatic anemia and cancer receiving chemotherapy. Participants
receiving NeoRecormon once weekly in accordance with the Summary of Product Characteristics
will be followed for 4 months.